Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 12 Parkinson Disease 4, Autosomal Dominant Lewy Body 8 Melanoma 6 Carcinoma, Renal Cell 6 Neoplasms 5 Neoplasm Metastasis 3 Esophageal Squamous Cell Carcinoma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Liver Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Advanced Solid Tumor 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Metastatic Castration-Resistant Prostate Cancer 1

Interventions

Docetaxel 3 pazopanib 2 Trabectedin 2 Doxorubicin 2 toripalimab 1 temsirolimus 1 sapanisertib 1 nilotinib 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 eribulin 1 cemiplimab 1 avelumab 1 abemaciclib 1 Sunitinib 1 Specimen Handling 1 Radiotherapy 1 Nivolumab 1 Methotrexate 1 Imatinib Mesylate 1 Ifosfamide 1 HhAntag691 1 Gemcitabine 1 Epirubicin 1 Dacarbazine 1 Cisplatin 1 Biopsy 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Leiomyosarcoma × lenvatinib × Clear all

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡